Controversies in COX-2 inhibitor therapy: closing remarks

Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S77-80.

Authors

S B Abramson¹, D E Furst, M C Hochberg, C Patrono

Affiliation

¹ Department of Rheumatology/Medicine, Hospital for Joint Surgery/NYU School of Medicine, New York, NY, USA.

PMID: 11695257

No abstract available

Publication types

Review

MeSH terms

Analgesics / therapeutic use
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
Arthritis, Rheumatoid / drug therapy
Arthritis, Rheumatoid / enzymology
Cardiovascular Diseases / chemically induced
Cardiovascular Diseases / pathology
Cyclooxygenase 2
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors / adverse effects
Cyclooxygenase Inhibitors / therapeutic use*
Humans
Isoenzymes / metabolism*
Kidney Diseases / chemically induced
Kidney Diseases / pathology
Membrane Proteins
Osteoarthritis / drug therapy
Osteoarthritis / enzymology
Prostaglandin-Endoperoxide Synthases / metabolism*
Randomized Controlled Trials as Topic

Substances

Analgesics
Anti-Inflammatory Agents, Non-Steroidal
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Isoenzymes
Membrane Proteins
Cyclooxygenase 2
PTGS2 protein, human
Prostaglandin-Endoperoxide Synthases